This is a routine conference update with no new data released. The next major catalyst is CHAPTER-3 topline data in Q3 2026. Monitor EAACI presentations for any incremental safety/efficacy signals, but no immediate trading action warranted.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $30.16entry
- T+1 · 6mo ago −3.51%α −3.77% · $29.10
- T+5 · 6mo ago +3.08%α +5.61% · $31.09
- T+20 · 5mo ago +15.09%α +16.88% · $34.71
- T+60 · 3mo ago +23.71%α +22.52% · $37.31
Price Chart
How similar events traded
Executive Summary
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Phase 3 RAPIDe-3 on-demand HAE data and Phase 2 CHAPTER-1 OLE prophylaxis data. The event is a routine scientific conference update with no new clinical data released today; the key catalyst remains the CHAPTER-3 topline data expected in Q3 2026.
Key Facts
- 8 abstracts accepted at EAACI 2026 (June 12-15, Istanbul), including 1 oral presentation of RAPIDe-3 Phase 3 on-demand HAE data
- 7 additional presentations cover cardiovascular safety, biomarker assay, RAPIDe-3 patient voices, and CHAPTER-1 OLE prophylaxis results
- CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis ongoing; topline data expected Q3 2026
- CREAATE Phase 3 study for AAE-C1INH (prophylactic and on-demand) also ongoing
- No new clinical data or regulatory milestones announced in this press release
Financial Impact
No financial data disclosed; event is a scientific conference update with no revenue or cost implications
Risk Factors
- No new clinical data released today; market may be disappointed by lack of material update
- CHAPTER-3 topline data in Q3 2026 is binary risk for the stock
- Competitive landscape includes existing injectable HAE therapies (Takhzyro, Firazyr) and oral competitors (Orladeyo)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303489 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers